{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:32:09Z","timestamp":1792675929960,"version":"4.5.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:00:00Z","timestamp":1461283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1038\/nrneurol.2016.44","type":"journal-article","created":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T05:39:54Z","timestamp":1461303594000},"page":"259-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":383,"title":["Myasthenia gravis \u2014 autoantibody characteristics and their implications for therapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Nils Erik","family":"Gilhus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir Olve","family":"Skeie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Romi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Lazaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Zisimopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates","family":"Tzartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,22]]},"reference":[{"key":"BFnrneurol201644_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/WCO.0b013e3283572588","volume":"25","author":"NE Gilhus","year":"2012","unstructured":"Gilhus, N. E. Myasthenia and neuromuscular junction. Curr. Opin. Neurol. 25, 523\u2013529 (2012).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrneurol201644_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","volume":"26","author":"L Querol","year":"2013","unstructured":"Querol, L. & Illa, I. Myasthenia and the neuromuscular junction. Curr. Opin. Neurol. 26, 459\u2013465 (2013).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrneurol201644_CR3","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","volume":"12","author":"JJGM Verschuuren","year":"2013","unstructured":"Verschuuren, J. J.G. M.  et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase, and low-density lipoprotein receptor-related protein 4. Autoimmune Rev. 12, 918\u2013923 (2013).","journal-title":"Autoimmune Rev."},{"key":"BFnrneurol201644_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus, N. E. & Verschuuren, J. J. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 14, 1023\u20131036 (2015).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol201644_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1212\/WNL.0b013e3181ad53c2","volume":"73","author":"AT Heldal","year":"2009","unstructured":"Heldal, A. T., Owe, J. F., Gilhus, N. E. & Romi, F. Seropositive myasthenia gravis; a nationwide epidemiologic study. Neurology 73, 150\u2013151 (2009).","journal-title":"Neurology"},{"key":"BFnrneurol201644_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr, A. S.  et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 10, 46 (2010).","journal-title":"BMC Neurol."},{"key":"BFnrneurol201644_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/jnnp.2005.072355","volume":"77","author":"JF Owe","year":"2006","unstructured":"Owe, J. F., Daltveit, A. K. & Gilhus, N. E. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J. Neurol. Neurosurg. Psychiatry 77, 203\u2013207 (2006).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201644_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie, G. O.  et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 17, 893\u2013902 (2010).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201644_CR9","doi-asserted-by":"publisher","first-page":"13928","DOI":"10.1038\/srep13928","volume":"5","author":"K Otsuka","year":"2015","unstructured":"Otsuka, K.  et al. Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signalling. Sci. Rep. 5, 13928 (2015).","journal-title":"Sci. Rep."},{"key":"BFnrneurol201644_CR10","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.1523\/JNEUROSCI.3381-14.2015","volume":"35","author":"J Messeant","year":"2015","unstructured":"Messeant, J.  et al. MuSK frizzled-like domain is critical for mammalian neuromuscular junction formation and maintenance. J. Neurosci. 35, 4926\u20134941 (2015).","journal-title":"J. Neurosci."},{"key":"BFnrneurol201644_CR11","first-page":"924","volume":"12","author":"P Zisimopoulou","year":"2013","unstructured":"Zisimopoulou, P., Brenner, T., Trakas, N. & Tzartos, S. J. Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmune Rev. 12, 924\u2013930 (2013).","journal-title":"Rev."},{"key":"BFnrneurol201644_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archneur.62.3.442","volume":"62","author":"F Romi","year":"2005","unstructured":"Romi, F., Skeie, G. O., Gilhus, N. E. & Aarli, J. A. Striational antibodies in myasthenia gravis; reactivity and possible clinical significance. Arch. Neurol. 62, 442\u2013446 (2005).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol201644_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","volume":"14","author":"F Romi","year":"2007","unstructured":"Romi, F., Aarli, J. A. & Gilhus, N. E. Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur. J. Neurol. 14, 617\u2013620 (2007).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201644_CR14","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","volume":"66","author":"S Suzuki","year":"2009","unstructured":"Suzuki, S.  et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch. Neurol. 66, 1334\u20131338 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol201644_CR15","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite, M. I.  et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131, 1940\u20131952 (2008).","journal-title":"Brain"},{"key":"BFnrneurol201644_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","volume":"284","author":"AI Tsonis","year":"2015","unstructured":"Tsonis, A. I.  et al. MuSK autoantibodies in myasthenia gravis detected by cell-based assay: a multinational study. J. Neuroimmunol. 284, 10\u201317 (2015).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201644_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jmb.2004.12.031","volume":"346","author":"N Unwin","year":"2005","unstructured":"Unwin, N. Refined structure of the nicotinic acetylcholine receptor at 4 \u00c5 resolution. J. Mol. Biol. 346, 967\u2013989 (2005).","journal-title":"J. Mol. Biol."},{"key":"BFnrneurol201644_CR18","doi-asserted-by":"publisher","first-page":"e108327","DOI":"10.1371\/journal.pone.0108327","volume":"9","author":"G Kordas","year":"2014","unstructured":"Kordas, G.  et al. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients. PLoS ONE 9, e108327 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201644_CR19","doi-asserted-by":"publisher","first-page":"e114060","DOI":"10.1371\/journal.pone.0114060","volume":"9","author":"AT Heldal","year":"2014","unstructured":"Heldal, A. T., Eide, G. E., Romi, F., Owe, J. F. & Gilhus, N. E. Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development. PLoS ONE 9, e114060 (2014).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201644_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2010.10.023","volume":"301","author":"L Yang","year":"2011","unstructured":"Yang, L.  et al. Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China. J. Neurol. Sci. 301, 71\u201376 (2011).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol201644_CR21","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","volume":"69","author":"S Jacob","year":"2012","unstructured":"Jacob, S., Viega, S. & Leite, M. I. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch. Neurol. 69, 994\u20131001 (2012).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol201644_CR22","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","volume":"72","author":"PMR Cruz","year":"2015","unstructured":"Cruz, P. M. R.  et al. Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol. 72, 642\u2013649 (2015).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol201644_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06808.x","volume":"1275","author":"JJ Plomp","year":"2012","unstructured":"Plomp, J. J., Huijbers, M. G., van der Maarel, S. M. & Verschuuren, J. J. Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis. Ann. NY Acad. Sci. 1275, 114\u2013122 (2012).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrneurol201644_CR24","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","volume":"77","author":"Y Kawakami","year":"2011","unstructured":"Kawakami, Y.  et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 77, 1819\u20131828 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol201644_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2014.05.037","volume":"343","author":"T Chang","year":"2014","unstructured":"Chang, T.  et al. Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population. J. Neurol. Sci. 343, 82\u201387 (2014).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol201644_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi, O.  et al. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 69, 418\u2013422 (2011).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201644_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou, P.  et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J. Autoimmun. 52, 139\u2013145 (2014).","journal-title":"J. Autoimmun."},{"key":"BFnrneurol201644_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","volume":"259","author":"A Pevzner","year":"2012","unstructured":"Pevzner, A.  et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibodynegative myasthenia gravis. J. Neurol. 259, 427\u2013435 (2012).","journal-title":"J. Neurol."},{"key":"BFnrneurol201644_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.brainres.2007.08.035","volume":"1177","author":"Y Lu","year":"2007","unstructured":"Lu, Y.  et al. A role for LRP4 in neuronal cell viability is related to apoE-binding. Brain Res. 1177, 19\u201328 (2007).","journal-title":"Brain Res."},{"key":"BFnrneurol201644_CR30","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1172\/JCI66039","volume":"123","author":"C Shen","year":"2013","unstructured":"Shen, C.  et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J. Clin. Invest. 123, 5190\u20135202 (2013).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol201644_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/acn3.26","volume":"2","author":"JS Tzartos","year":"2014","unstructured":"Tzartos, J. S.  et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann. Clin. Trans. Neurol. 2, 80\u201387 (2014).","journal-title":"Ann. Clin. Trans. Neurol."},{"key":"BFnrneurol201644_CR32","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","volume":"82","author":"C Gasperi","year":"2014","unstructured":"Gasperi, C.  et al. Anti-agrin autoantibodies in myasthenia gravis. Neurology 82, 1976\u20131983 (2014).","journal-title":"Neurology"},{"key":"BFnrneurol201644_CR33","doi-asserted-by":"publisher","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","volume":"9","author":"B Zhang","year":"2014","unstructured":"Zhang, B.  et al. Autoantibodies to agrin in myasthenia gravis. PloS ONE 9, e91816 (2014).","journal-title":"PloS ONE"},{"key":"BFnrneurol201644_CR34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.mod.2012.09.004","volume":"130","author":"V Witzemann","year":"2013","unstructured":"Witzemann, V., Chevessier, F., Pacifici, P. G. & Yampolsky, P. The neuromuscular junction: selective remodeling of synaptic regulators at the nerve\/muscle interface. Mech. Dev. 130, 402\u2013411 (2013).","journal-title":"Mech. Dev."},{"key":"BFnrneurol201644_CR35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.12271","volume":"130","author":"P Szczudlik","year":"2014","unstructured":"Szczudlik, P.  et al. Anti-titin antibody in early and late onset myasthenia gravis. Acta Neurol. Scand. 130, 229\u2013233 (2014).","journal-title":"Acta Neurol. Scand."},{"key":"BFnrneurol201644_CR36","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1242\/jeb.105361","volume":"217","author":"K Powers","year":"2014","unstructured":"Powers, K.  et al. Titin force is enhanced in actively stretched skeletal muscle. J. Exp. Biol. 217, 3629\u20133636 (2014).","journal-title":"J. Exp. Biol."},{"key":"BFnrneurol201644_CR37","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1212\/WNL.43.8.1581","volume":"43","author":"M Gautel","year":"1993","unstructured":"Gautel, M.  et al. Titin antibodies in myasthenia gravis: identification of a major antigenic region of titin. Neurol. 43, 1381\u20131385 (1993).","journal-title":"Neurol."},{"key":"BFnrneurol201644_CR38","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","volume":"259","author":"F Romi","year":"2012","unstructured":"Romi, F.  et al. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J. Neurol. 259, 1312\u20131316 (2012).","journal-title":"J. Neurol."},{"key":"BFnrneurol201644_CR39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ene.12234","volume":"21","author":"S Suzuki","year":"2014","unstructured":"Suzuki, S.  et al. Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur. J. Neurol. 21, 223\u2013230 (2014).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201644_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/mus.10294","volume":"27","author":"GO Skeie","year":"2003","unstructured":"Skeie, G. O.  et al. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro. Muscle Nerve 27, 81\u201389 (2003).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201644_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","volume":"348","author":"KM Zoltowska","year":"2015","unstructured":"Zoltowska, K. M.  et al. Collagen Q: a potential target for autoantibodies in myasthenia gravis. J. Neurol. Sci. 348, 241\u2013244 (2015).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol201644_CR42","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","volume":"13","author":"E Gallardo","year":"2014","unstructured":"Gallardo, E.  et al. Cortactin autoantibodies in myasthenia gravis. Autoimmun. Rev. 13, 1003\u20131007 (2014).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneurol201644_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1212\/WNL.55.1.7","volume":"55","author":"GH Gronseth","year":"2000","unstructured":"Gronseth, G. H. & Barohn, R. J. Thymectomy for autoimmune myasthenia gravis (an evidence-based review). Neurology 55, 7\u201315 (2000).","journal-title":"Neurology"},{"key":"BFnrneurol201644_CR44","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1542\/peds.2013-0814","volume":"132","author":"J VanderPluym","year":"2013","unstructured":"VanderPluym, J.  et al. Clinical characteristics of pediatric myasthenia: a surveillance study. Pediatrics 132, e939\u2013944 (2013).","journal-title":"Pediatrics"},{"key":"BFnrneurol201644_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill, J. T., Sanders, D. B. & Evoli, A. Anti-MuSK antibody myasthenia gravis; clinical findings and response to treatment in two large cohorts. Muscle Nerve 44, 36\u201340 (2011).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201644_CR46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/ene.12359","volume":"21","author":"E Kerty","year":"2014","unstructured":"Kerty, E., Elsais, A., Argov, Z., Evoli, A. & Gilhus, N. E. EFNS\/ENS guidelines for the treatment of ocular myasthenia gravis. Eur. J. Neurol. 21, 687\u2013693 (2014).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201644_CR47","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace, J., Newsom-Davis, J. & Lecky, B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50, 1778\u20131783 (1998).","journal-title":"Neurology"},{"key":"BFnrneurol201644_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1749-6632.2012.06780.x","volume":"1275","author":"M Benatar","year":"2012","unstructured":"Benatar, M., Sanders, D. B., Wolfe, G. I., McDermott, M. P. & Tawil, R. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann. NY Acad. Sci. 1275, 17\u201322 (2012).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrneurol201644_CR49","first-page":"CD005081","volume":"12","author":"M Benatar","year":"2012","unstructured":"Benatar, M. & Kaminski, H. Medical and surgical treatment for ocular myasthenia (review). Cochrane Database Syst. Rev. 12, CD005081 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrneurol201644_CR50","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","volume":"85","author":"F Norwood","year":"2014","unstructured":"Norwood, F.  et al. Myasthenia in pregnancy; best practice guidelines from a UK multispeciality working group. J. Neurol. Neurosurg. Psychiatry 85, 538\u2013543 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201644_CR51","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","volume":"41","author":"MK Hehir","year":"2010","unstructured":"Hehir, M. K.  et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis; outcomes in 102 patients. Muscle Nerve 41, 593\u2013598 (2010).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201644_CR52","doi-asserted-by":"crossref","unstructured":"The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71, 394\u2013399 (2008).","DOI":"10.1212\/01.wnl.0000312373.67493.7f"},{"key":"BFnrneurol201644_CR53","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","volume":"71","author":"DB Sanders","year":"2008","unstructured":"Sanders, D. B.  et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71, 400\u2013406 (2008).","journal-title":"Neurology"},{"key":"BFnrneurol201644_CR54","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J Diaz-Manera","year":"2012","unstructured":"Diaz-Manera, J.  et al. Long-lasting treatment of rituximab in MuSK myasthenia. Neurology 78, 189\u2013193 (2012).","journal-title":"Neurology"},{"key":"BFnrneurol201644_CR55","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","volume":"84","author":"B Keung","year":"2013","unstructured":"Keung, B.  et al. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J. Neurol. Neurosurg. Psychiatry 84, 1407\u20131409 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201644_CR56","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","volume":"262","author":"R Iorio","year":"2015","unstructured":"Iorio, R.  et al. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J. Neurol. 262, 1115\u20131119 (2015).","journal-title":"J. Neurol."},{"key":"BFnrneurol201644_CR57","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat, A.  et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann. Neurol. 68, 797\u2013805 (2010).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201644_CR58","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth, D.  et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76, 2017\u20132023 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol201644_CR59","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nrneurol.2011.14","volume":"7","author":"NE Gilhus","year":"2011","unstructured":"Gilhus, N. E. Acute treatment for myasthenia gravis. Nat. Rev. Neurol. 7, 132\u2013134 (2011).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrneurol201644_CR60","first-page":"CD002277","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos, P., Chevret, S. & Toyka, K. V. Intravenous immunoglobulin for myasthenia gravis (review). Cochrane Database Syst. Rev. 12, CD002277 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrneurol201644_CR61","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2014.12.001","volume":"278","author":"K Lazaridis","year":"2015","unstructured":"Lazaridis, K.  et al. Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains. J. Neuroimmunol. 278, 19\u201325 (2015).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201644_CR62","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamaneurol.2013.3553","volume":"70","author":"L Steinman","year":"2013","unstructured":"Steinman, L. The road not taken: antigen-specific therapy and neuroinflammatory disease. JAMA Neurol. 70, 1100\u20131101 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol201644_CR63","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","volume":"12","author":"A Marx","year":"2013","unstructured":"Marx, A.  et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun. Rev. 12, 875\u2013884 (2013).","journal-title":"Autoimmun. Rev."},{"key":"BFnrneurol201644_CR64","first-page":"CD008111","volume":"10","author":"G Cea","year":"2013","unstructured":"Cea, G., Benatar, M., Verdugo, R. J. & Salinas, R. A. Thymectomy for non-thymomatous myasthenia gravis (review). Cochrane Database Syst. Rev. 10, CD008111 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrneurol201644_CR65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/1477-7819-11-157","volume":"11","author":"B Ye","year":"2013","unstructured":"Ye, B.  et al. Video-assisted thoracoscopic surgery versus robotic-assisted thoracoscopic surgery in the surgical treatment of Masaoka stage I thymoma. World J. Surg. Oncol. 11, 157\u2013162 (2013).","journal-title":"World J. Surg. Oncol."},{"key":"BFnrneurol201644_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ene.12599","volume":"22","author":"NE Gilhus","year":"2015","unstructured":"Gilhus, N. E., Nacu, A., Andersen, J. B. & Owe, J. F. Myasthenia gravis and risks for comorbidity. Eur. J. Neurol. 22, 17\u201323 (2015).","journal-title":"Eur. J. Neurol."},{"key":"BFnrneurol201644_CR67","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/mus.24745","volume":"52","author":"FY Chiou-Tan","year":"2015","unstructured":"Chiou-Tan, F. Y. & Gilchrist, J. M. Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert\u2013Eaton myasthenic syndrome: review of recent literature. Muscle Nerve 52, 455\u2013462 (2015).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201644_CR68","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/joim.12163","volume":"275","author":"MG Huijbers","year":"2013","unstructured":"Huijbers, M. G.  et al. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis. J. Intern. Med. 275, 12\u201326 (2013).","journal-title":"J. Intern. Med."},{"key":"BFnrneurol201644_CR69","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jmb.2006.09.019","volume":"364","author":"AL Stiegler","year":"2006","unstructured":"Stiegler, A. L., Burden, S. J. & Hubbard, S. R. Crystal structure of the agrin-responsive immunoglobulin-like domains 1 and 2 of the receptor tyrosine kinase MuSK. J. Mol. Biol. 364, 424\u2013433 (2006).","journal-title":"J. Mol. Biol."},{"key":"BFnrneurol201644_CR70","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0969-2126(02)00814-6","volume":"10","author":"JH Till","year":"2002","unstructured":"Till, J. H.  et al. Crystal structure of the MuSK tyrosine kinase: insights into receptor autoregulation. Structure 10, 1187\u20131196 (2002).","journal-title":"Structure"},{"key":"BFnrneurol201644_CR71","doi-asserted-by":"publisher","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","volume":"8","author":"I Koneczny","year":"2013","unstructured":"Koneczny, I., Cossins, J., Waters, P., Beeson, D. & Vincent, A. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS ONE 8, e80695 (2013).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201644_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmb.2009.07.091","volume":"393","author":"AL Stiegler","year":"2009","unstructured":"Stiegler, A. L., Burden, S. J. & Hubbard, S. R. Crystal structure of the frizzled-like cysteine-rich domain of the receptor tyrosine kinase MuSK. J. Mol. Biol. 393, 1\u20139 (2009).","journal-title":"J. Mol. Biol."},{"key":"BFnrneurol201644_CR73","doi-asserted-by":"publisher","first-page":"e7930","DOI":"10.1371\/journal.pone.0007930","volume":"4","author":"HY Choi","year":"2009","unstructured":"Choi, H. Y.  et al. Lrp4, a novel receptor for dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 4, e7930 (2009).","journal-title":"PLoS ONE"},{"key":"BFnrneurol201644_CR74","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1101\/gad.180885.111","volume":"26","author":"Y Zong","year":"2012","unstructured":"Zong, Y.  et al. Structural basis of agrin\u2013LRP4\u2013MuSK signaling. Genes Dev. 26, 247\u2013258 (2012).","journal-title":"Genes Dev."},{"key":"BFnrneurol201644_CR75","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","volume":"69","author":"B Zhang","year":"2012","unstructured":"Zhang, B.  et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch. Neurol. 69, 445\u2013451 (2012).","journal-title":"Arch. Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.44","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2016.44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:19:48Z","timestamp":1684455588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2016.44"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,22]]},"references-count":75,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["BFnrneurol201644"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2016.44","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,22]]},"assertion":[{"value":"22 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.E.G. has received speaker's honoraria from Octapharma, Baxter and Merck Serono. P.Z. is co-inventor in a patent related to myasthenia gravis therapy and diagnosis. S.T. is co-inventor in two patnets related to myasthenia gravis therapy and diagnosis, and is shareholder and scientific advisor of Tzartos Neurodiagnostics. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}